Intraocular use of Lucentis (Ranibizumab) in the treatment of acute central serous chorioretinopathy, an inflammatory diesease of the retina.
Phase 1
- Conditions
- Acute central serous chorioretinopathy (CSC) CSC is an acute idiopathic chorioretinopathy. While the majority of cases is characterized by a self-limited course, chronic CSC is seen in up to one third of patients. Case reports and first results of small case series have recently been published about the use of intravitreal bevacizumab with promising results. It is not known if Lucentis (Ranibizumab) may yield same or better results in CSC and prove superior to observation alone.Therapeutic area: Diseases [C] - Eye Diseases [C11]
- Registration Number
- EUCTR2010-020902-13-AT
- Lead Sponsor
- niversitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Innsbruck
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
Patient age >18 a, <60 a
Diagnosis of CSC by optical coherence tomography and fluorenscence angiography
Symptom duration less than three months
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Present ocular, intraocular, or periocular infection
Recurrent CSC
St.p. intraocular surgery within the past year
St.p. Argon laser coagulation of the retina
St.p. Photodynamic therapy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method